DSM Biologics provides and develops technologies relevant for optimized mammalian cell culture processes.
The contract covers the process development and cGMP manufacturing by DSM of their lead product iNKT mAb.
Upon exposure to microbial and viral pathogens NKT cells secrete high levels of specific cytokines which stimulate the immune system to eliminate pathogens.
DSM Biologics president Karen King said with a range of mammalian bioreactor sizes from 50 liters up to 1000 liters and, process and analytical development capabilities, DSM offers development and production flexibility combined with economy.
NKT Therapeutics chief scientific officer Alem Truneh said manipulation of NKT cells is an exciting new therapeutic strategy.